176 related articles for article (PubMed ID: 35589408)
1.
Ouvrard E; Mestier L; Boursier C; Lachachi B; Sahakian N; Chevalier E; Mikail N; Carullo J; Bando-Delaunay A; Walter T; Malouf GG; Addeo P; Poncet G; Sebag F; Lebtahi R; Goichot B; Taïeb D; Imperiale A
J Nucl Med; 2022 Dec; 63(12):1865-1870. PubMed ID: 35589408
[TBL] [Abstract][Full Text] [Related]
2. Value of
Imperiale A; Boursier C; Sahakian N; Ouvrard E; Chevalier E; Sebag F; Addeo P; Taïeb D
J Nucl Med; 2022 Mar; 63(3):384-388. PubMed ID: 34272321
[TBL] [Abstract][Full Text] [Related]
3. Intraindividual comparison of
Ouvrard E; Chevalier E; Addeo P; Sahakian N; Detour J; Goichot B; Bachellier P; Karcher G; Taïeb D; Imperiale A
Clin Endocrinol (Oxf); 2021 Jan; 94(1):66-73. PubMed ID: 32790887
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity Comparison of
Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of metastases outside the liver and abdominal lymph nodes on
Wedin M; Janson ET; Wallin G; Sundin A; Daskalakis K
J Neuroendocrinol; 2024 May; 36(5):e13391. PubMed ID: 38590270
[TBL] [Abstract][Full Text] [Related]
6. Head-to-Head Comparison of
Johnbeck CB; Knigge U; Loft A; Berthelsen AK; Mortensen J; Oturai P; Langer SW; Elema DR; Kjaer A
J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of
Sawicki LM; Deuschl C; Beiderwellen K; Ruhlmann V; Poeppel TD; Heusch P; Lahner H; Führer D; Bockisch A; Herrmann K; Forsting M; Antoch G; Umutlu L
Eur Radiol; 2017 Oct; 27(10):4091-4099. PubMed ID: 28439648
[TBL] [Abstract][Full Text] [Related]
8.
Kroiss AS; Uprimny C; Shulkin BL; Gruber L; Frech A; Url C; Riechelmann H; Sprinzl GM; Thomé C; Treglia G; Kjaer A; Fraedrich G; Virgolini IJ
Nucl Med Biol; 2019 Apr; 71():47-53. PubMed ID: 31152973
[TBL] [Abstract][Full Text] [Related]
9. Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours.
Kumar R; Sharma P; Garg P; Karunanithi S; Naswa N; Sharma R; Thulkar S; Lata S; Malhotra A
Eur Radiol; 2011 Nov; 21(11):2408-16. PubMed ID: 21750886
[TBL] [Abstract][Full Text] [Related]
10. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
[TBL] [Abstract][Full Text] [Related]
11.
Kroiss AS; Uprimny C; Shulkin BL; Gruber L; Frech A; Jazbec T; Girod PP; Url C; Thomé C; Riechelmann H; Sprinzl GM; Fraedrich G; Virgolini IJ
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(2):94-99. PubMed ID: 30630744
[TBL] [Abstract][Full Text] [Related]
12. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients.
Putzer D; Gabriel M; Kendler D; Henninger B; Knoflach M; Kroiss A; Vonguggenberg E; Warwitz B; Virgolini IJ
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):68-75. PubMed ID: 20168288
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 18F-DOPA Versus 68Ga-DOTATOC as Preferred PET Imaging Tracer in Well-Differentiated Neuroendocrine Neoplasms.
Veenstra EB; de Groot DJA; Brouwers AH; Walenkamp AME; Noordzij W
Clin Nucl Med; 2021 Mar; 46(3):195-200. PubMed ID: 33323729
[TBL] [Abstract][Full Text] [Related]
14. Dual tracer 68Ga-DOTATOC and 18F-FDG PET/computed tomography radiomics in pancreatic neuroendocrine neoplasms: an endearing tool for preoperative risk assessment.
Mapelli P; Partelli S; Salgarello M; Doraku J; Pasetto S; Rancoita PMV; Muffatti F; Bettinardi V; Presotto L; Andreasi V; Gianolli L; Picchio M; Falconi M
Nucl Med Commun; 2020 Sep; 41(9):896-905. PubMed ID: 32796478
[TBL] [Abstract][Full Text] [Related]
15. Staging of neuroendocrine tumours: comparison of [⁶⁸Ga]DOTATOC multiphase PET/CT and whole-body MRI.
Schraml C; Schwenzer NF; Sperling O; Aschoff P; Lichy MP; Müller M; Brendle C; Werner MK; Claussen CD; Pfannenberg C
Cancer Imaging; 2013 Mar; 13(1):63-72. PubMed ID: 23466785
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Whole-Body PET Volumetric Parameters Extracted from
Thuillier P; Liberini V; Grimaldi S; Rampado O; Gallio E; Santi B; Arvat E; Piovesan A; Filippi R; Abgral R; Molinari F; Deandreis D
J Nucl Med; 2022 Jul; 63(7):1014-1020. PubMed ID: 34740949
[TBL] [Abstract][Full Text] [Related]
17. Localization of Unknown Primary Site with
Menda Y; O'Dorisio TM; Howe JR; Schultz M; Dillon JS; Dick D; Watkins GL; Ginader T; Bushnell DL; Sunderland JJ; Zamba GKD; Graham M; O'Dorisio MS
J Nucl Med; 2017 Jul; 58(7):1054-1057. PubMed ID: 28153957
[TBL] [Abstract][Full Text] [Related]
18. Head-to-head comparison between [
He Q; Zhang Z; Zhang L; Zhang B; Long Y; Zhang Y; Liao Z; Zha Z; Zhang X
Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):1989-2001. PubMed ID: 38300262
[TBL] [Abstract][Full Text] [Related]
19. 68Ga-DOTATOC PET/CT in Patients with Iodine- and 18F-FDG-Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin.
Binse I; Poeppel TD; Ruhlmann M; Ezziddin S; Görges R; Sabet A; Beiderwellen K; Bockisch A; Rosenbaum-Krumme SJ
J Nucl Med; 2016 Oct; 57(10):1512-1517. PubMed ID: 27033897
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of atypical
Gossili F; Almasi CE; Zacho HD
Hell J Nucl Med; 2023; 26(2):94-98. PubMed ID: 37527044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
